Wave Life Sciences Ltd. (WVE)

Market Cap	639.32M
Revenue (ttm)	112.91M
Net Income (ttm)	-61.92M
Shares Out	122.48M
EPS (ttm)	-0.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	895,822
Open	5.25
Previous Close	5.24
Day's Range	5.07 - 5.35
52-Week Range	3.50 - 7.67
Beta	-1.04
Analysts	Buy
Price Target	12.29 (+135.44%)
Earnings Date	Aug 1, 2024

About WVE

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for t...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 11, 2015
• Employees: 266
• Stock Exchange: NASDAQ
• Ticker Symbol: WVE

Financial Performance

In 2023, WVE's revenue was $113.31 million, an increase of 3005.10% compared to the previous year's $3.65 million. Losses were -$57.51 million, -64.46% less than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for WVE stock is "Buy." The 12-month stock price forecast is $12.29, which is an increase of 135.44% from the latest price.

Price Target

$12.29

(135.44% upside)

Analyst Consensus: Buy